Intensity Therapeutics Reports Positive Phase 2 Data for INT230-6 in TNBC, Resumes Sarcoma Trial Enrollment
INTS is trading near its 52-week low of $4.633 (10% above the low).
Summary
Intensity Therapeutics reported Q1 2026 financial results and significant clinical updates, including positive preliminary Phase 2 data for INT230-6 in TNBC and plans to resume enrollment in its Phase 3 sarcoma study.
Key Events · Product Development and Regulatory · INTS
-
Positive Phase 2 TNBC Data
Preliminary INVINCIBLE-4 study results showed 71.4% pathological complete response (pCR) in the INT230-6 + standard of care arm compared to 33% in the standard of care alone arm for triple-negative breast cancer patients, with fewer severe adverse events.
-
Sarcoma Trial Resumption
The company plans to resume enrollment in its INVINCIBLE-3 Phase 3 study for soft tissue sarcoma in a limited number of U.S. sites by Q3 2026, after a pause due to funding constraints.
-
Q1 2026 Financials
Intensity Therapeutics reported a net loss of $2.4 million for the first quarter of 2026, an improvement from $3.3 million in Q1 2025, and held $10.2 million in cash and cash equivalents as of March 31, 2026.
-
Funding Strategy
The company continues to rely on its $60 million At-The-Market (ATM) facility, established in March 2026, to support ongoing operations and clinical trials, as it seeks additional funding.
Analysis · INTS · Life Sciences
This 8-K provides crucial operational updates alongside its Q1 2026 financial results, which were also reported in a 10-Q today. The most significant new information is the positive preliminary Phase 2 data from the INVINCIBLE-4 study in triple-negative breast cancer (TNBC), showing a higher pathological complete response (pCR) rate (71.4% vs. 33%) and fewer adverse events with INT230-6 plus standard of care. The company also announced plans to resume enrollment in its INVINCIBLE-3 sarcoma study, which had been paused due to funding constraints. While the company reiterates its low cash position and reliance on its $60 million ATM facility (as noted in the concurrent 10-Q and prior filings), these clinical advancements provide a much-needed positive catalyst and demonstrate progress in its pipeline, potentially extending its operational runway and attracting further investment.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INTS was trading at $5.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13M. The 52-week trading range was $4.63 to $43.50. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.